Assignee
ONCONOVA THERAPEUTICS INC
US·10 granted patents·10 pending applications·29 citations·filing 2002–2024
Top patents by PatentIndex Score
20 records- 0181US11382877B2Formulation of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailabilityONCONOVA THERAPEUTICS INC·Filed 2018·Granted Jul 12, 2022·1 cites·14 claims
- 0280US6579988B2Processes for the preparation of 1,5-diarylpyrazolesONCONOVA THERAPEUTICS INC·Filed 2002·Granted Jun 17, 2003·8 cites·11 claims
- 0379US10098862B1Formulations with enhanced stability and bioavailability for administration of (E)-2,6-dialkoxystyryl 4-substituted benzylsulfonesONCONOVA THERAPEUTICS INC·Filed 2017·Granted Oct 16, 2018·2 cites·33 claims
- 0477US7161031B2Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disordersONCONOVA THERAPEUTICS INC·Filed 2003·Granted Jan 9, 2007·11 cites·77 claims
- 0570US6706927B2Alkyne ketonesONCONOVA THERAPEUTICS INC·Filed 2003·Granted Mar 16, 2004·3 cites·2 claims
- 0666US6906196B2Processes for the preparation of 1,5-diaryl-3-substituted-pyrazolesONCONOVA THERAPEUTICS INC·Filed 2002·Granted Jun 14, 2005·2 cites·9 claims
- 0763US6809204B2Processes for the preparation of substituted isoxazoles and 2-isoxazolinesONCONOVA THERAPEUTICS INC·Filed 2002·Granted Oct 26, 2004·1 cites·25 claims
- 0860US10576050B2Methods and compositions for treatment of cancerONCONOVA THERAPEUTICS INC·Filed 2013·Granted Mar 3, 2020·1 cites·10 claims
- 0955US2009247624A1Formulations of radioprotective alpha beta unsaturated aryl sulfonesONCONOVA THERAPEUTICS INC·Filed 2007·Application pending·0 cites
- 1055US2011028504A1Formulation of radioprotective alpha beta unsaturated aryl sulfonesONCONOVA THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 1154US7094903B2Processes for the preparation of substituted isoxazoles and 2-isoxazolinesONCONOVA THERAPEUTICS INC·Filed 2004·Granted Aug 22, 2006·0 cites·22 claims
- 1253US2011250184A1Methods for determining efficacy of a therapeutic regimen against deleterious effects of cytotoxic agents in humanONCONOVA THERAPEUTICS INC·Filed 2009·Application pending·0 cites
- 1350US2024366610A1Methods and compositions for treating cancerONCONOVA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1450US2024374600A1Methods and compositions for treating cancerONCONOVA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1550US2024374601A1Methods and compositions for treating cancerONCONOVA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1649US2024299326A1Methods and compositions for treating cancerONCONOVA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1749US2024269099A1Methods and compositions for treating cancerONCONOVA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1847US9713597B2Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfoneONCONOVA THERAPEUTICS INC·Filed 2015·Granted Jul 25, 2017·0 cites·9 claims
- 1944US2022002293A18-cyclopentyl-7-oxo-2-(4-piperazin-1-yl-phenylamino)-7, 8-dihydro-pyrido [2,3-d]pyrimidine-6-carbonitrile and uses thereof in treating proliferative disordersONCONOVA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2040US2016102363A1Methods and compositions for predicting therapeutic efficacy of kinase inhibitors in patients with myelodysplastic syndrome or related disordersONCONOVA THERAPEUTICS INC·Filed 2014·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ONCONOVA THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →